Philadelphia, PA, United States of America

Mirela Meka

This inventor holds 2 USPTO granted patents. Top assignee: Numoda Technologies, Inc.. Active years: 2009-2011.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 16(Granted Patents)


Company Filing History:


Years Active: 2009-2011

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Mirela Meka: Innovator in Clinical Trial Management

Introduction

Mirela Meka is a prominent inventor based in Philadelphia, PA (US). She has made significant contributions to the field of clinical trial management through her innovative patents. With a total of 2 patents, Mirela has developed solutions that enhance the efficiency and effectiveness of clinical trial studies.

Latest Patents

Mirela's latest patents include a method and apparatus for accounting and contracting for clinical trial studies. This invention models a clinical trial study to automatically generate business intelligence information. The software application program she developed incorporates equations and business rules that define processes, timelines, and deliverables associated with clinical trials. It is designed to manage budget items, contracted entities, and expected cash flow needs, ultimately streamlining the accounting process for clinical trials.

Career Highlights

Mirela Meka is currently employed at Numoda Technologies, Inc., where she continues to innovate in the field of clinical trials. Her work focuses on improving the management and operational aspects of clinical studies, ensuring that they are conducted efficiently and effectively.

Collaborations

Mirela collaborates with talented professionals such as Fernando F Alves and Ann S Vurimindi, contributing to a dynamic work environment that fosters innovation and creativity.

Conclusion

Mirela Meka's contributions to clinical trial management through her patents demonstrate her commitment to advancing the field. Her innovative solutions are paving the way for more efficient clinical studies, ultimately benefiting the healthcare industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…